[{"id":"87a89c62-067c-468b-af11-fef3c384939e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04530552","created_at":"2024-02-13T21:25:45.706Z","updated_at":"2025-02-25T17:36:44.962Z","phase":"Phase 2","brief_title":"Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland","source_id_and_acronym":"NCT04530552","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • CD4 • NCAM1","pipe":" | ","alterations":" NCAM1 positive","tags":["CD8 • CD4 • NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NCAM1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 07/23/2021","start_date":" 07/23/2021","primary_txt":" Primary completion: 11/06/2024","primary_completion_date":" 11/06/2024","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2025-01-29"},{"id":"821ba445-ef11-495f-8892-3f8670ca41f4","acronym":"PIONEER","url":"https://clinicaltrials.gov/study/NCT04939480","created_at":"2021-06-25T22:54:07.374Z","updated_at":"2024-07-02T16:35:07.670Z","phase":"Phase 2","brief_title":"Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN","source_id_and_acronym":"NCT04939480 - PIONEER","lead_sponsor":"University Hospital, Essen","biomarkers":" GZMB","pipe":" | ","alterations":" NCAM1 positive","tags":["GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NCAM1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 10/06/2021","start_date":" 10/06/2021","primary_txt":" Primary completion: 03/14/2024","primary_completion_date":" 03/14/2024","study_txt":" Completion: 03/14/2024","study_completion_date":" 03/14/2024","last_update_posted":"2024-04-25"},{"id":"a4c2ebb0-b6de-4797-9fa4-06a37d8a44b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT02122081","created_at":"2021-01-18T09:49:45.733Z","updated_at":"2024-07-02T16:35:36.447Z","phase":"Phase 1","brief_title":"Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies","source_id_and_acronym":"NCT02122081","lead_sponsor":"Sumithira Vasu","biomarkers":" CD8 • HLA-DRB1 • CD4 • NCAM1 • HLA-B • HLA-C","pipe":" | ","alterations":" NCAM1 positive","tags":["CD8 • HLA-DRB1 • CD4 • NCAM1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NCAM1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • cyclophosphamide intravenous • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 07/27/2015","start_date":" 07/27/2015","primary_txt":" Primary completion: 09/06/2022","primary_completion_date":" 09/06/2022","study_txt":" Completion: 09/06/2022","study_completion_date":" 09/06/2022","last_update_posted":"2023-09-21"},{"id":"e563983d-59ef-4c13-a972-23c5f2266842","acronym":"","url":"https://clinicaltrials.gov/study/NCT02890758","created_at":"2021-01-18T14:11:18.504Z","updated_at":"2024-07-02T16:35:55.216Z","phase":"Phase 1","brief_title":"Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803","source_id_and_acronym":"NCT02890758","lead_sponsor":"Brenda Cooper, MD","biomarkers":" ABL1 • BCR • NCAM1","pipe":" | ","alterations":" NCAM1 positive","tags":["ABL1 • BCR • NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NCAM1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anktiva (nogapendekin alfa inbakicept-pmln)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 05/22/2018","start_date":" 05/22/2018","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 02/17/2023","study_completion_date":" 02/17/2023","last_update_posted":"2023-02-20"},{"id":"07353550-6b14-4214-83e7-f317aeb92293","acronym":"","url":"https://clinicaltrials.gov/study/NCT03619954","created_at":"2021-01-18T17:47:16.618Z","updated_at":"2024-07-02T16:37:08.145Z","phase":"Phase 1","brief_title":"NK Cells Infusion for Advanced Malignancies","source_id_and_acronym":"NCT03619954","lead_sponsor":"Anhui Provincial Hospital","biomarkers":" NCAM1","pipe":" | ","alterations":" NCAM1 positive","tags":["NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NCAM1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 07/01/2018","start_date":" 07/01/2018","primary_txt":" Primary completion: 07/01/2019","primary_completion_date":" 07/01/2019","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2018-08-08"}]